DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Brugada syndrome 8 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBrugada syndrome 8 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for brugada syndrome 8 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
hyperpolarization activated cyclic nucleotide gated potassium channel 4 (HCN4) — HCN4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pc1drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6GYN · 3.4 Å · ligand 1,2-DIACYL-SN-GLYCERO-3-PHOSPHOCHOLINE (PC1). Experimental structure, not a prediction.
What the evidence adds up to
The 2013 study of a Spanish family with Brugada syndrome identified a nonsense variation, p.E61X, in the RANGRF gene in the index case and five other family members. All six individuals had a normal electrocardiogram at rest. After a flecainide challenge, only two of the relatives showed a type 1 Brugada pattern on ECG. The authors conclude that p.E61X_RANGRF is a rare genetic variation with an uncertain role in Brugada syndrome. No drug was tested or proposed in this study.
Two review articles from 2019 and 2020 describe ongoing controversy in the field. The 2019 review states that more than three decades after its initial description in 1993, Brugada syndrome remains engulfed in controversy, with unresolved challenges in diagnosis, risk stratification of asymptomatic patients, and pharmacological and interventional strategies. The 2020 review examines the many names given to the syndrome and notes that the cases in an early article by Martini et al. do not meet the mandatory diagnostic criterion of a type 1 Brugada ECG pattern. Neither review reports any drug treatment data or clinical trial results.
No evidence from these abstracts supports any drug repurposing for Brugada syndrome. The genetic variant discussed has an uncertain pathogenic role, and the broader literature emphasises unresolved diagnostic and risk-stratification problems. What is missing is any prospective trial testing a specific drug in a well-characterised patient cohort, a clear molecular target validated by functional studies, and a reliable method to stratify asymptomatic carriers who might benefit from intervention.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cardiology Journal · 2013 · 17 citations · open access
Brugada syndrome and p.E61X_RANGRF
AbstractBACKGROUND: Brugada syndrome is an inherited cardiac condition transmitted with an autosomal dominant pattern which can lead to sudden cardiac death from malignant ventricular arrhythmias. The RANGRF gene has recently been proposed to be associated with Brugada syndrome. This gene encodes the MOG1 protein, a co-factor required for the full functioning of the cardiac sodium channel Nav1.5. The nonsense p.E61X genetic variation in the RANGRF gene has been postulated as responsible for Brugada syndrome although no clear association has been established. METHODS: We clinically and genetically evaluated a Spanish family diagnosed with Brugada syndrome. A comprehensive genetic analysis of all genes to date responsible for Brugada syndrome was performed in the index case. RESULTS: The index case was clinically diagnosed with Brugada syndrome after flecainide test. We identified a nonsense variation (p.E61X) in the index case and in other five family members. All of them showed a normal electrocardiogram in basal conditions. Flecainide test unmasked a type 1 Brugada syndrome electrocardiogram only in two of the relatives. CONCLUSIONS: We suggest that p.E61X_RANGRF is a rare genetic variation with an uncertain role in Brugada Syndrome. Further studies must be performed to elucidate the potential pathogenic role of p.E61X_RANGRF in Brugada Syndrome.
European Cardiology Review · 2019 · 12 citations · open access
Current Controversies and Challenges in Brugada Syndrome
AbstractMore than three decades since its initial description in 1993, Brugada syndrome remains engulfed in controversy. This review aims to shed light on the main challenges surrounding the diagnostic pathway and criteria, risk stratification of asymptomatic patients, pharmacological and interventional risk modification strategies as well as our current pathophysiological understanding of the disease.
Journal of Human Growth and Development · 2020 · 4 citations · open access
The numerous denominations of the Brugada syndrome and proposal about how to put an end to an old controversy - a historical-critical perspective
AbstractBackgroung: The eponymous Brugada Syndrome (BrS) in honor of its discovery as an independent entity by the Spanish/ Catalan Brugada brothers, Pedro and Josep, has deserved numerous denominations derived mainly from the clinical genotype/phenotype correlation. The purpose of this manuscript is to present and analyze the nomenclatures that this intriguing and challenging syndrome has received over the past 28 years. We also compared the main features between cases from the first report of the Brugada brothers and an article by Martini et al. The nomenclatures used by these authors are closely linked to the BrS, but the cases (except one) presented in the article by Martini et al do not present the type 1 Brugada ECG pattern, which is mandatory for the diagnosis of BrS.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
